Search results
KRAS inhibitors: The next frontier beckons
Pharmaceutical Technology via Yahoo Finance· 17 hours agoKrazati and Lumakras both target KRAS G12C, which is a prominent mutation seen in NSCLC. However, certain cancers such as pancreatic cancer< ...
Jimmy Carter's grandson says former president is 'coming to the end'— what to know about his health
The Today Show via AOL· 1 day agoAfterward, he continued to receive immunotherapy treatments. Jimmy Carter has a family history with ...
Who Is the Golden Bachelorette? All About Joan Vassos
People via Yahoo News· 1 day agoJoan Vassos, a former contestant on Gerry Turner's season of 'The Golden Bachelor,' has been named...
Miss America carries strong ties to Pikes Peak region
Colorado Springs Gazette· 4 days agoAir Force 2nd Lieutenant Madison Marsh, a 2023 Air Force Academy graduate, says she doesn’t see...
New cancer-detecting blood test now available at University Hospitals
WKYC Cleveland· 3 hours agoIn 2017, after four attempts, Ohio finally passed cancer presumption legislation for firefighters,...
See how Madison Marsh balances her duties as a US Air Force officer and Miss America
Business Insider· 2 hours agoThis story is available exclusively to Business Insider subscribers. Become an Insider and start...
Earnings call: Oncolytics Biotech details progress in cancer studies By Investing.com
Investing.com· 6 days agoCEO Dr. Matt Coffey outlined the company's plans to begin registrational track studies for their...
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration...
NewMediaWire via Yahoo Finance· 1 day agoFREMONT, CA - (NewMediaWire) - May 15, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a...
Earnings call: Panbela Therapeutics reports on ASPIRE trial progress By Investing.com
Investing.com· 12 hours agoPanbela Therapeutics, the biopharmaceutical company focused on developing treatments for cancer, has...
Third Party Withdraws Appeal Related to Cantargia Patent
Digital Journal· 7 hours agoThe main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer
